Atorvastatin: What the Clinical Trials Show
Atorvastatin is the most widely prescribed statin in the UK and the default choice in NICE guidance for lowering cardiovascular risk. Its reputation rests on a series of large randomised trials run over two decades. Our editors walk through the key studies, what they measured, and how their results translate into everyday prescribing.
How atorvastatin works
Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis in the liver. With less cholesterol produced internally, liver cells increase the number of LDL receptors on their surface and pull more LDL particles out of the bloodstream. The result is a fall in LDL cholesterol that depends on the dose.
LDL cholesterol is causally linked to atherosclerosis. Genetic studies, observational cohorts and randomised trials all point in the same direction: the lower the LDL exposure over time, the lower the risk of heart attack and ischaemic stroke. Atorvastatin was among the drugs that helped establish this principle.
Compared with older statins such as simvastatin and pravastatin, atorvastatin is more potent per milligram and has a longer half-life of its active metabolites. This allows once-daily dosing at any time of day, which is convenient and supports adherence.
In the UK atorvastatin is a prescription-only medicine. NICE guideline NG238 (2023) recommends atorvastatin 20 mg for primary prevention and 80 mg for people with established cardiovascular disease, adjusted according to response, interactions and tolerability. These figures come from official guidance and are not a substitute for a prescriber's decision.
Primary prevention: ASCOT-LLA and CARDS
The Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA) enrolled over 10,000 people with hypertension, additional risk factors and average or below-average cholesterol. Participants received atorvastatin 10 mg or placebo. The trial was stopped early, after a median of around 3.3 years, because of a clear reduction in non-fatal heart attacks and fatal coronary heart disease.
ASCOT-LLA was important because it showed benefit in people whose cholesterol would not traditionally have been considered "high". The key variable turned out to be overall cardiovascular risk, not a single cholesterol reading, which is the logic behind today's QRISK-based approach in England.
The Collaborative Atorvastatin Diabetes Study (CARDS) tested the same dose in nearly 2,840 people with type 2 diabetes and no prior cardiovascular disease. It too was stopped early, showing a substantial reduction in major cardiovascular events, including stroke. CARDS strongly influenced the recommendation to offer statins to many people with diabetes.
Both trials used a modest dose, yet produced meaningful benefit within a few years. Later meta-analyses by the Cholesterol Treatment Trialists' Collaboration confirmed that the relative risk reduction per unit of LDL lowering is broadly consistent across groups.
| Trial | Population | Comparison | Main finding |
|---|---|---|---|
| ASCOT-LLA (2003) | Hypertension, no CHD | Atorvastatin 10 mg vs placebo | Fewer coronary events; stopped early |
| CARDS (2004) | Type 2 diabetes, no CVD | Atorvastatin 10 mg vs placebo | Fewer major CV events incl. stroke |
| PROVE-IT (2004) | Recent acute coronary syndrome | Atorvastatin 80 mg vs pravastatin 40 mg | Intensive therapy reduced events |
| TNT (2005) | Stable coronary disease | Atorvastatin 80 mg vs 10 mg | Fewer major CV events with high dose |
| SPARCL (2006) | Recent stroke or TIA | Atorvastatin 80 mg vs placebo | Fewer recurrent strokes |
Secondary prevention: higher intensity, bigger benefit
PROVE-IT TIMI 22 compared atorvastatin 80 mg with pravastatin 40 mg in more than 4,000 patients shortly after an acute coronary syndrome. The intensive atorvastatin arm achieved lower LDL levels and a lower rate of the combined endpoint of death and major cardiovascular events over about two years.
The Treating to New Targets (TNT) trial asked a cleaner question: in people with stable coronary disease, does 80 mg do better than 10 mg of the same drug? Around 10,000 patients were followed for nearly five years. The high dose reduced major cardiovascular events further, at the cost of more frequent rises in liver enzymes.
SPARCL tested atorvastatin 80 mg against placebo in people who had recently had a stroke or transient ischaemic attack but no known coronary disease. Recurrent stroke and major cardiovascular events were reduced. A small increase in haemorrhagic stroke was observed, which remains a point of discussion in people with prior bleeding.
Taken together, these trials established a principle that underpins current guidance: in people with established disease, more intensive LDL lowering produces greater benefit. The CTT meta-analysis of 2010 quantified this as roughly a one-fifth reduction in major vascular events for each 1 mmol/L reduction in LDL cholesterol.
Side effects: what the trials and later studies found
Muscle symptoms are the most discussed problem. In blinded trials, reports of muscle aches were only slightly more common, if at all, on atorvastatin than on placebo. Serious muscle injury (rhabdomyolysis) is rare but real, and risk increases with high doses, interacting drugs, hypothyroidism and kidney impairment.
The SAMSON n-of-1 trial, published in 2020, gave people who had previously stopped statins because of side effects alternating months of statin, placebo and no tablet. Around 90% of the symptom burden experienced on statin was also experienced on placebo, highlighting the "nocebo" effect.
Other findings from the trial programme and later analyses include:
- a small increase in the risk of new-onset type 2 diabetes, mainly in people already close to the diagnostic threshold;
- dose-related rises in liver transaminases, usually without symptoms and reversible;
- interactions with drugs that inhibit CYP3A4, such as clarithromycin and some antifungals, and with large amounts of grapefruit juice.
Regulators and guideline bodies consider that, for people at meaningful cardiovascular risk, the benefits clearly outweigh these risks. The decision is still individual and should take into account personal preferences and other medicines.
Relevance for active people and athletes
Regular exercise and statins are not mutually exclusive. Many people with familial hypercholesterolaemia or high cardiovascular risk train hard while taking atorvastatin. Some report more muscle soreness after unaccustomed or eccentric exercise, and studies have explored whether statins blunt training adaptation, with inconsistent results.
Practical steps include reporting persistent unexplained muscle pain or weakness to the prescriber, asking for a creatine kinase test if symptoms are significant, and avoiding testing CK immediately after a hard session, since exercise itself raises it. Thyroid function and vitamin D are often checked when muscle symptoms appear.
Atorvastatin is not on the WADA Prohibited List. However, people who use anabolic steroids sometimes take statins themselves to "protect" against lipid changes. Self-prescribing is unsafe: it does not remove the many other cardiovascular effects of such substances and masks warning signs that should prompt medical review.
Lifestyle measures remain complementary. Physical activity, dietary fibre, replacing saturated with unsaturated fats and not smoking all reduce cardiovascular risk and can lower the dose needed to reach targets.
Conclusions of the editorial team
Atorvastatin is one of the best-studied medicines in cardiology. Randomised trials in primary prevention (ASCOT-LLA, CARDS) and in established disease (PROVE-IT, TNT, SPARCL) consistently showed fewer heart attacks and strokes.
The size of the benefit depends on baseline risk and on how much LDL is lowered, which is why higher-intensity treatment is preferred after a cardiovascular event.
Side effects exist but are less frequent than commonly believed, as blinded trials and the SAMSON study suggest. Open discussion with a clinician is the best way to address concerns.
Related reading on our site includes our guides to preparing for an apolipoprotein B test, to ezetimibe interactions, and to how training affects blood lipids.
References
- Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA). Lancet. 2003;361(9364):1149–1158.
- Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet. 2004;364(9435):685–696.
- Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504.
- LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435.
- Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–559.
- Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
- Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182–2184.
